

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09770943
Filing Date	2001-01-25
First Named Inventor	Eyal Raz
Art Unit	1646
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	UCSD-173CON

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
			<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09770943
Filing Date	2001-01-25
First Named Inventor	Eyal Raz
Art Unit	1646
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	UCSD-173CON

1	CHENG, X et al., "Suppressive Oligodeoxynucleotides Inhibit Atherosclerosis in ApoE -/- Mice Through Modulation of Th1/Th2 Balance"; Science Direct; Journal of Molecular and Cellular Cardiology 45 (2008) pp. 168-175	<input type="checkbox"/>
2	DONG, L et al., "Suppressive Oligonucleotides Protect Against Collagen-Induced Arthritis in Mice"; Arthritis & Rheumatism; Vol. 50, No. 5, (May 2004) pp.1686-1680	<input type="checkbox"/>
3	DONG, L et al., "Suppressive Oligodeoxynucleotides Delay the Onset of Glomerulonephritis and Prolong Survival in Lupus-Prone NZB x NZW Mice"; Arthritis & Rheumatism, Vol. 52, No. 2, (February 2005); pp. 651-658	<input type="checkbox"/>
4	GAUPP, S. et al., "Amelioration of Experimental Autoimmune Encephalomyelitis in IL-4Ra -/- Mice Implicates Compensatory Up-Regulation of the Th2-Type Cytokines"; Immunopathology and Infectious Disease; The American Journal of Pathology, Vol. 173, No. 1 (July 2008) 11 pp.	<input type="checkbox"/>
5	HO, P. et al., "An Immunomodulatory CpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems"; The Journal of Immunology; The American Association of Immunologists (2003) pp. 4920-4926	<input type="checkbox"/>
6	HO, P. et al., "A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease"; The Journal of Immunology; The American Association of Immunologists (2005) pp. 6226-6234.	<input type="checkbox"/>
7	JIN, L. et al., "A Th-1 Recognized Peptide P277, When Tandemly Repeated, Enhances a Th2 Immune Response toward Effective Vaccines against Autoimmune Diabetes in Nonobese Diabetic Mice"; The Journal of Immunology; The American Association of Immunologists (2007) pp. 58-63	<input type="checkbox"/>
8	RAMSHAW, I. et al., "DNA Vaccines for the Treatment of Autoimmune Disease"; Immunology and Cell Biology (1997) 75, pp. 409-413	<input type="checkbox"/>
9	SHIROTA, H. et al., "Suppressive Oligodeoxynucleotides Inhibit Th1 Differentiation by Blocking IFN- γ - and IL-12-Mediated Signaling" The Journal of Immunology; The American Association of Immunologists (2004) pp. 5002-5007	<input type="checkbox"/>
10	YOUNG, D.A. et al., "IL-4, IL-10, IL-13, and TGF- β from an Altered Peptide Ligand-Specific Th2 Cell Clone Down-Regulate Adoptive Transfer of Experimental Autoimmune Encephalomyelitis"; The American Association of Immunologists (2000) pp. 3563-3572	<input type="checkbox"/>
11	ZEUNER, R., "Reduction of CpG-Induced Arthritis by Suppressive Oligodeoxynucleotides"; Arthritis & Rheumatism, Vol. 46, No. 8, (August 2002); pp. 2219-2224	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09770943
Filing Date	2001-01-25
First Named Inventor	Eyal Raz
Art Unit	1646
Examiner Name	Patricia Ann Duffy
Attorney Docket Number	UCSD-173CON

12



If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature | /Patricia Duffy/ | Date Considered | 02/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.